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ABSTRACT 
Surgical trauma results in a variety of physiological reactions in the body, including 
transient insulin resistance. The effect of surgery on postoperative wellbeing has been 
linked to this insulin resistance, which can be prevented through the ingestion of 
carbohydrate-rich liquid before surgery. The aim of this Thesis is to improve the clinical 
usefulness of the intravenous glucose tolerance test (IVGTT) by shortening the sampling 
time from 3 hours to 75 minutes and to use the IVGTT, and two other simple tests 
(QUICKI and HOMA-IR), to study whether most or all of the beneficial effects of the 
carbohydrate drink on postoperative insulin resistance can be explained by the water 
component of the drink. 
Study I: Twenty healthy volunteers underwent a 75-min IVGTT. Insulin resistance was 
then assessed using the hyperinsulinemic glucose clamp technique, regarded as the gold-
standard method. The resultant measurements of plasma glucose and insulin concentrations 
during the IVGTT were combined, using a variety of algorithms, allowing the insulin 
resistance, as measured by the clamp, to be predicted in 2/3 and 4/5 of subjects. 
Study II: Sixty non-diabetic patients scheduled for hip replacement surgery were 
randomized into preoperative fasting (control), drink flavored water (placebo) or 
carbohydrate-rich liquid group. An IVGTT was performed the day before surgery, 
immediately afterwards, and the day after the surgery. No statistically significant 
differences were found with regard to glucose clearance, insulin resistance, postoperative 
complications or wellbeing between the three study groups. 
Study III: A double-blind clinical trial was performed in which twenty-three non-diabetic 
patients underwent both an IVGTT and a hyperinsulinemic glucose clamp test on the day 
before and two days after hip replacement surgery. Half of the patients received a 
carbohydrate-rich liquid before the surgery; the other half received a placebo. There was a 
similar development of insulin resistance in both groups, but those who received a 
carbohydrate-rich liquid showed an increase in β-cell activity. 
Study IV: Twenty-two patients from Study III were used to compare the insulin resistance 
results obtained from two dynamic tests (our short 7-sample IVGTT and the glucose clamp) 
and two static tests (QUICKI and HOMA-IR). The static tests showed slightly weaker 
linearity and larger residual errors compared to IVGTT in estimating insulin resistance 
before and after surgery. More importantly, they greatly underestimated the degree of 
surgery-induced insulin resistance, suggesting that they should not be used for that purpose. 
Conclusions 
The simplified IVGTT results strongly correlated with those obtained used the 
hyperinsulinemic glucose clamp technique, which makes its use possible in the clinical 
setting. There was no statistical difference in surgery-induced insulin resistance between 
those who had received a carbohydrate-rich beverage or flavored water prior to hip 
replacement surgery. In addition, similar outcomes were seen in patients who had received 
a pretreatment carbohydrate-rich beverage, water or fasted preoperatively with regard to 
well-being and complications. HOMA and QUICKI should not be used to assess surgery-
induced changes in insulin resistance. 
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 1 LIST OF ABBREVATIONS 
 
 
AUC Area under the curve 
β-cell Beta-cell 
BIA Bioimpedance 
C-peptide Connecting peptide 
CL Clearance 
ECF and ICF Extra- and intracellular fluid 
ELISA Enzyme-linked immunosorbent assays 
FFA Free fatty acids 
FSIGT Frequently sampled intravenous glucose tolerance test 
GLUT-4 Glucose transporter isoform-4 
HOMA Homeostasis model assessment 
IL-6 Interleukin-6 
IVGTT Intravenous glucose tolerance test 
MAP Mean arterial pressure 
Mbw Metabolism of glucose after correction for body weight 
OA Osteoarthritis 
OGTT Oral glucose tolerance test 
QUICKI Quantitative insulin sensitivity check index 
r Correlation coefficient 
r2 Square of the correlation coefficient 
RCT Randomized control study 
THR Total hip replacement 
T½ Half-life 
VAS Visual analog scale 
Vd Volume of distribution 
W-BQ12 A well-being questionnaire with 12 questions 
3-MH 3- methyl-histidine 
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2  INTRODUCTION 
My interest regarding hydration and nutritional support prior to elective hip replacement 
surgery arose as a result the extent to which patient recovery differs following the procedure. 
Many patients experience fatigue for several weeks after the surgery, and this is generally 
accepted as an expected effect of the surgery. Previous orthopedic research has mostly focused 
on the outcome of various implants, such as plates, screws and artificial joints. However, 
we easily overlook the importance of patient well-being and convalescence after surgery. 
OSTEOARTHRITIS 
Joint surfaces are covered by a layer of articular 
cartilage a few millimeters thick. This cartilage 
distributes load across the joint and reduces friction 
during movement. The cartilage matrix can be likened 
to a fiber-reinforced, water retention gel with 
hygroscopic properties. The synovial tissue which lines 
the joint capsule secretes and is lubricated by a thin 
layer of viscous synovial fluid, which contains a high 
concentration of hyaluronic acid. 
On loading, some water is squeezed out of the cartilage 
tissue, only to be sucked in again when the load 
decreases. It has been suggested that an optimized loading of the hip joint, through weight 
reduction and exercise, can slow the progression of the disease (Messier, Loeser et al. 
2000)(Swedish social board),  
The principle focus of the treatment of osteoarthritis is to reduce pain and improve function. 
Treatments techniques may be divided into basic, adjunctive and surgical. Currently, there are 
no drugs that directly affect the disease. In the United States, osteoarthritis is estimated to cost 
the society 215 billion dollars per year. In Sweden, health economists have calculated that the 
costs related to musculoskeletal diseases are higher than those for all the diseases that affect the 
brain and peripheral nervous system combined. Joint disease is the most common chronic 
disease in older people; more common than hypertension, heart disease or diabetes 
(www.boneandjointdecade.org). 
Common symptoms of joint disease are pain and functional impairment, leading to a reduced 
quality of life. Osteoarthritis can occur in any joint and the most commonly affected are the 
knee and the hip. People with osteoarthritis of the knee or hip have an increased risk of 
premature death from cardiovascular disease, with the mortality rate increasing in proportion to 
the degree of joint function impairment (www.boneandjointdecade.org). It is therefore 
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important to investigate the risk-factors that can be influenced, e.g., high blood pressure, 
hyperlipidemia, smoking, obesity and low physical activity. 
Osteoarthritis, in common with over- or under loading of a joint, changes the metabolic 
equilibrium, resulting in an imbalance between degradation and repair. The cells try to carry 
out repairs, but are not able to regenerate a functional matrix and, as a result, the shock-
absorbing ability of the joint is progressively lost. 
The incidence of osteoarthritis is strongly age-related, rising steeply after 50 years of age. 
Approximately 15 percent of men and women aged 35–55 years suffer from pain in the knee 
and/or the hip, often caused by osteoarthritis. In people aged 65 years or older, osteoarthritis is 
the most common cause of physical functional impairment. For women over 60, osteoarthritis 
is the fifth most common disease. 
More rarely, osteoarthritis can occur in young and middle-aged people, often associated with 
overweight or obesity, or as a result of a previous joint injury. The risk of osteoarthritis in both 
knees and hips is related to the degree of excess bodyweight. Weight and previous injury are 
of greater importance in predicting the development of osteoarthritis than factors such as 
work-related loading of the joints. There is also a substantial hereditary risk of developing 
osteoarthritis. 
The degree of joint changes and the symptoms experienced are often not directly related. This 
emphasizes the importance of using disease symptoms to guide diagnosis and treatment. 
In cases where a precipitating cause can be identified there might be a time lapse of between 
10 and 30 years before osteoarthritis can be diagnosed on X-ray. The primary radiographic 
criterion for a diagnosis of osteoarthritis is a decreased joint space, which, in turn, is a result of 
the destroyed articular cartilage. It follows that a routine X-ray examination can only diagnose 
advanced osteoarthritis, when the cartilage has already been destroyed. 
In early stages, X-rays are essentially normal. Severe cartilage damage can, however, be seen 
on arthroscopy. This may be a contributing factor to the poor correlation between the 
radiographic signs of osteoarthritis and pain. The relationship with pain is clearer when the 
radiographic signs of osteoarthritis are severe. 
It is pain that usually leads a patient to approach the health service. Initially, pain occurs on 
movement or load-bearing. Later, the pain is also experienced at rest and overnight. Recent 
studies have shown that the osteoarthritis, as measured by X-ray, is not always progressive and 
in approximately half of cases the radiographic changes may not alter for many years{Haugen, 
2013}. Patients who receive a new hip joint are advised to refrain from physical activity which 
may place large loads on the prosthesis and instead encouraged to undertake exercise such as 
cycling and Nordic walking. 
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HIP PROSTHESIS 
Elective hip replacement surgery is a very common operation worldwide. In 2011, the number 
of total hip arthroplasties in Sweden was the same as in 2010. Approximately 16,000 
operations were carried out; a rate of 170 per 100,000 inhabitants. The number of hemi-
arthroplasties undertaken was also unchanged, with approximately 4,500 operations performed. 
The numbers of reoperations were 2,200 and 330 respectively. 
Modern hip replacement surgery was developed by John Charnley 
in the late 1960´s. His concept of a cemented femoral stem made 
of a metal alloy, with a socket of polyethylene (total hip 
replacement/total hemiarthroplasty) (Fig.1.). This became the 
dominant system used over subsequent years, and it still remains 
to be the main option for  hip arthroplasty in Sweden. There are 
also another concept where only the femoral stem and head but 
not the acetabulum are replaced (hemi-arthroplasty) 
With the help of the Swedish Hip Arthroplasty Register, which 
started in Gothenburg in 1980, it has been possible to examine 
how various implant systems perform over time. Charnley’s 
original prosthesis has proved, over many years, to be one of the 
best, with a revision rate (reoperation because of prosthetic 
loosening) of less than 10% after 10 years. To date, a total 
of 23,000 operations have been entered into this registry. 
According to data from the Swedish Hip Registry, there are now several newer implant systems 
with even lower revision rates over a 10-year period. The Swedish prosthetics market is now 
dominated entirely by five different models, all of which are cemented. 
Even by the early 1970´s, surgeons had begun experimenting with different concepts to that 
developed by Charnley. Initial interest focused on whether it was possible to anchor the 
prosthesis without using the bone cement that Charnley had used and a large number of 
prostheses using uncemented anchoring were developed. By the early 1980´s, many surgeons 
believed that they could solve the anchoring problems by pushing or screwing the prostheses. 
However, the Swedish Registry reveals that most of the newer systems have had a significantly 
poorer outcome over time, compared to cemented systems. After initially adopting the 
uncemented systems, most orthopedic surgeons in Sweden have now largely reverted to 
cemented prostheses. As a result, Sweden now has the lowest revision rate of hip prostheses in 
the world. 
New uncemented prostheses have appeared on the market. These are coated with a 
material that allows bone to grow into it, resulting in better anchoring, and have shown good 
results over time (Yamada, Yoshihara et al. 2009). The type of fixation ultimately used is 
determined by the bone appearance and quality (Hailer, Garellick et al. 2010). 
Fig. 1. 
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Hip resurfacing is an alternative method that is used primarily in younger and physically active 
patients, especially in males. The principle is that the femoral head is not replaced but the 
articular cartilage is removed and then replaced by a metallic coat (Fig.2.) (Westacott, 
McArthur et al. 2013). 
Today, minimally invasive surgical techniques have been developed requiring only a small skin 
incision and the duration of hospital stay and period of convalescence have decreased as a 
result. However, the learning curve is long and there is a risk of non-optimal placement of the 
prosthesis due to poor overwiev of the operation field (De Geest, Vansintjan et al. 2013). 
Focus on the insertion of the prosthesis 
In recent times attention has also been focused on the approach used to insert the prosthesis. 
Techniques which do not require osteotomy of the trochanteric part of the hip have gradually 
been developed (Weaver 1975). 
Hardinge developed a technique in which half the gluteus medius muscle is detached from the 
greater trochanter (Hardinge 1982). This is a very common surgical approach and reduces the 
risk of backward dislocation. The problem with this technique is that patients may initially  
develop a Trendelenburg limp. Furthermore, there is evidence that the reinserted gluteus 
medius sometimes detaches, giving rise to a persistent limp. 
Over the same time period, a technique was developed in which  the short external rotators at 
the back of the hip joint are loosened. The technology was not, in itself, new (Gibson 1950), 
but had not previously been used for the insertion of the prosthetic hip. It can result in minor 
postoperative problems with paralysis resulting in a slightly higher risk of implant dislocation. 
This is the result of a reduced backwards stability so that the prosthesis can dislocate in 
certain 
Fig. 2. 
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situations, e.g., when the patient raises up from a low chair and then bends the trunk 
forward while bending the hip (Weeden, Paprosky et al. 2003). 
There are a large number of studies that compare the results of the front and rear approaches in 
hip replacement, and it is not possible to firmly conclude which is the better technique. The 
most important consideration is, of course, that the surgeon should be familiar with the 
technology that they are using. 
No description can be found in the literature concerning how long a conventional incision 
should be. There is considerable variation, depending on the patient height and weight. Most 
orthopedic surgeons would probably use an incision of approximately 20 cm for the insertion 
of a hip prosthesis in the conventional way. 
The average length of stay for a patient undergoing total hip replacement is largely dependent 
on the patient's overall state of health. An otherwise healthy 70-year-old patient would, on 
average, have a hospital stay of 3–5 days, while an 85-year-old patient with other diseases 
might have a hospital stay of twice that. There are also local variations regarding treatment 
times. In healthier patients, the information that they receive preoperatively can also help to 
shorten the length of their stay. The average operation time for conventional hip replacement 
surgery is about 90 min. 
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SURGERY AND METABOLIC STRESS 
Transient insulin resistance is one of the most basic reactions to injury (Thorell, Nygren et al. 
1999). The neuroendocrine and inflammatory systems become activated within minutes and 
put the body into a metabolic state of stress (Kratzing 2011, Vigano, Cereda et al. 2012). This 
state involves a cascade of reactions including reduced insulin sensitivity (similar to type 2 
diabetes) (Brandi, Frediani et al. 1990, Ljungqvist, Nygren et al. 2000), increased stress 
hormone secretion, and increased muscle breakdown (Hedstrom, Ljungqvist et al. 2006, 
Ljungqvist, Soop et al. 2007). The stress-response arrests anabolic processes and initiates a 
catabolic state, enabling the release of reserves of fuel and building blocks from all bodily 
stores (fat, carbohydrate, and protein) with the production of acute phase proteins and increased 
tissue healing (Thorell, Nygren et al. 1999, Ljungqvist 2010). A central feature of this massive 
change in metabolism is the development of insulin resistance. 
Insulin is the body’s most important anabolic hormone but its effectiveness is reduced in 
catabolic states (Ljungqvist, Thorell et al. 1994, Thorell, Efendic et al. 1994). In studies by 
Thorell et al. (Thorell, Efendic et al. 1993, Thorell, Nygren et al. 1999) the degree of insulin 
resistance was found to be related to the magnitude of the surgery. This change in metabolism 
may last for up to 2 weeks, even after a moderate surgical stress (Thorell, Nygren et al. 1999). 
Studies suggest that insulin resistance is one of the key mechanisms triggering several common 
surgical complications (Ljungqvist, Nygren et al. 2000). 
Traditionally, insulin resistance has been regarded as the way the body responds to stress, and it 
was usually believed to be beneficial (Ljungqvist, Nygren et al. 2000). Indeed, studies of 
certain severely stressful situations have shown insulin resistance to be a key to survival 
(Robinson and van Soeren 2004). This is true in cases of acute hemorrhage, where insulin 
resistance is necessary to mobilize glucose to assist in fluid movement and plasma replacement 
(Ljungqvist, Sandberg et al. 1989, Ljungqvist and Alibegovic 1994). However, recent 
studies of elective surgical patients have suggested that in modern surgical practice insulin 
resistance is harmful and prolongs recovery (Thorell, Nygren et al. 1999). Occasionally, 
nausea and fatigue may persist for several weeks of the convalescence period (Hausel, 
Nygren et al. 2005, Ashby, Grocott et al. 2008, Lauwick, Kaba et al. 2009). Hence, these 
studies suggest that insulin resistance is an important parameter to monitor after surgery 
because it might influence the course of the patients´ convalescence (Wiklund and Romanus 
1991, Ostendorf, van Stel et al. 2004, Riediger, Doering et al. 2010). 
Several studies have shown that transiently reduced insulin sensitivity may be limited, or 
prevented, by giving insulin (Brandi, Frediani et al. 1990), a preoperative intravenous infusion  
(Ljungqvist, Thorell et al. 1994, Nygren, Thorell et al. 1998) or oral administration of 
glucose (Nygren, Soop et al. 1999, Ljungqvist 2010). 
A recently published meta-analysis (Li, Wang et al. 2012), based on 13 trials comparing a 
carbohydrate drink with placebo (flavored drinking water), included three randomized studies 
with patients undergoing total hip replacement (Soop, Nygren et al. 2001, Soop, Nygren et al. 
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2004, Aronsson, Al-Ani et al. 2009). A smaller increase in glucose level was observed at 
the end of surgery in those patients who had been given a carbohydrate drink, compared with 
placebo, but there were no statistical differences in insulin level at the end of surgery or in 
glucose levels at the induction of anesthesia. The overall result of this meta-analysis, which 
also included colorectal surgery, laparoscopic cholecystectomy, and cardiac surgery, could 
not make a definitive conclusion regarding the usefulness of a carbohydrate drink in hip 
surgery, as it only included a small number of such studies. In addition, the quality of the 
evidence obtained for most outcomes was relatively low. It is not clear whether a 
carbohydrate drink can affect postoperative catabolism, although insulin resistance has been 
correlated with catabolism and intracellular dehydration following hysterectomy (Strandberg 
and Hahn 2005). The benefit of a nutritional carbohydrate drink with regard to overall 
postoperative wellbeing was, when I began my studies, still unknown (Wiklund and 
Romanus 1991, Ostendorf, van Stel et al. 2004). 
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INSULIN AND C-PEPTIDE 
Insulin (Fig. 3.) is an anabolic hormone which is secreted by the 
pancreatic β-cells in response to increased circulating levels of 
glucose and amino acids. It is essential for maintaining glucose 
homeostasis and prevents hyperglycemia by reducing hepatic 
glucose output, by decreasing gluconeogenesis and 
glycogenolysis, and by increasing the rate of glucose uptake, 
primarily into skeletal muscle, adipose tissue and the liver 
(Thorell, Nygren et al. 1999). Glucose is then stored, as 
Fig.. 3 . glycogen, in the liver and  skeletal muscle. In muscle  and  fat
cells, the clearance of circulating glucose depends on the 
insulin-stimulated translocation of the glucose transporter iso-form-4 (GLUT-4) to the cell 
surface (Fig. 4.) (Shulman 2000). In skeletal muscle, GLUT-4 is the rate-controlling step for 
insulin-stimulated muscle glycogen synthesis (Shulman 2000). 
Insulin also profoundly affects lipid metabolism, increasing lipid synthesis in liver and fat cells 
and attenuating free fatty acid (FFA) release from triglycerides (Kahn 2003). The action of 
insulin is initiated through binding to, and activation of, the cell surface receptor (Saltiel and 
Kahn 2001). The receptor then undergoes a series of intra-molecular reactions, stimulated by 
insulin, resulting in glucose uptake, through the activation of GLUT-4. The body reacts to 
surgical stress with a change in metabolism to a catabolic state. This, in turn, can affect these 
intra-molecular reactions, resulting in insulin resistance. This is further aggravated by the 
fasting state commonly found preoperatively. 
Fig. 4. 
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Fig. 3.
C-peptide is a byproduct of insulin production 
and is cleaved off during storage in the β-cells 
in the pancreas secretion granules (Fig. 5.). 
Exogenous insulin does not contain C-peptide, 
making it possible to assess endogenous 
insulin production, which is important in 
diabetes care (Hope, Jones et al. 2013). Unlike 
insulin, C-peptide is not taken up by the liver. 
The uptake of insulin by the liver is about 50% 
of the total insulin secretion under basal 
conditions, but varies between individuals and 
is influenced by factors such as liver disease 
and other metabolic conditions (Pacini and 
Mari 2003). The C-peptide concentration can 
therefore reflect the secretion of insulin in a 
more precise way than insulin concentration 
measurements can. It is eliminated through 
kidney glomeruli and metabolized mainly in 
the tubules (Pietropaolo 
2013). 
INSULIN RESISTANCE 
The opposite of insulin sensitivity is insulin resistance. In this condition more insulin is 
required to slow sugar production by the liver and to stimulate the uptake of sugar into the 
muscles, i.e., the normal amount of circulating insulin is insufficient to regulate glucose uptake 
by the cells (Reaven 1997). 
Insulin resistance is defined as an impaired glycemic response to either exogenous or 
endogenous insulin action. Initially, the pancreatic cells (β-cells) manage to compensate for 
insulin resistance through an increase in insulin secretion, often seen in clinical practice as an 
increase in plasma insulin concentrations (Hunter and Garvey 1998, Saltiel 2000). 
This might occur in response to some kind of stress (such as surgery), infection, intake of 
cortisone, too little exercise and if there are high blood lipid levels. 
High blood lipid levels increase the deposition of lipids in the liver and muscles, which in turn 
slows insulin action (insulin resistance) (Fellander, Nordenstrom et al. 1994, Reaven 1997, 
Bacha, Lee et al. 2010). Exercise, i.e. muscle work, has the effect of reducing the amount of 
insulin required to maintain normal blood sugar levels, which is comparable with enhanced 
insulin sensitivity (Wallberg-Henriksson, Rincon et al. 1998).
It has been observed that some risk factors for type 2 diabetes and cardiovascular disease 
(coronary heart disease, stroke, peripheral vascular disease) can interact with each other, 
increasing the overall risk of morbidity or mortality (Reaven 1997, Laakso 1999). This 
accumulation of risk factors is usually called “the metabolic syndrome”. This syndrome can be 
Fig. 5. 
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defined in many different ways, but no internationally accepted definition exists today. Many 
scientists also query whether the syndrome exists at all, but most agree that the presence of 
several of the syndrome criteria increases the risk of developing type 2 diabetes and 
cardiovascular disease (Kahn, Buse et al. 2005). The risk factors included in the metabolic 
syndrome: are abdominal obesity (increased waist circumference: for men >102 cm and for 
women >88 cm), elevated blood lipids, increased blood pressure, and elevated fasting plasma 
glucose (Borai, Livingstone et al. 2007, Muniyappa, Lee et al. 2008, Bacha, Lee et al. 2010).  
INSULIN SECRETION AND DISPOSITION INDEX 
The assessment of pancreatic β-cell function in humans is challenging because of the complex 
interplay between insulin sensitivity, insulin 
secretion, and hepatic insulin extraction, which 
interact with each other in complicated closed 
loop systems (Ahren and Pacini 2004, Cobelli, 
Toffolo et al. 2007, Defronzo 2009). Basically, 
the relationship between insulin sensitivity and 
insulin secretion can be described by an 
approximate hyperbola (Fig. 6), (Kahn, Prigeon 
et al. 1993, Ferrannini and Mari 1998, 
Muniyappa, Lee et al. 2008) with the product of 
the two variables being constant for individuals 
with the same degree of glucose tolerance, i.e. 
disposition index (Kahn 2003, Faerch, Brons et 
al. 2010). 
Several techniques can be used to estimate 
pancreatic β-cell function, such as data derived 
from the frequently sampled i.v. glucose tolerance  
test (FSIGT), the oral glucose tolerance test (OGTT),  
the glucose-dependent arginine stimulation test or the euglycemic 
hyperinsulinemic clamp technique, in combination with a test of insulin secretion. 
MEASUREMENTS OF INSULIN SENSITIVITY AND INSULIN SECRETION 
A problem encountered when assessing  and insulin sensitivity is that the measurements are 
demanding and complex. The test widely used, and regarded as the gold standard, is the 
hyperinsulinemic euglycemic clamp (DeFronzo, Tobin et al. 1979). 
The principle behind this glucose clamp test is to maintain a predetermined glucose level 
during a constant insulin infusion. Assessment of insulin secretion can be made by the 
hyperglycemic glucose clamp. Here, the insulin secretion is measured in a situation of steady 
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Fig. 6
state hyperglycemia. In both cases, measurements of the plasma insulin and C-peptide 
concentrations (allowing prehepatic insulin secretion to be calculated) are made while the 
infusion rate of glucose is governed by frequent measures of plasma glucose on site. In this test 
multiple samples of insulin and C-peptide concentrations are analyzed. 
A conventional glucose tolerance test gives a good indication of insulin resistance but is 
difficult to implement during surgery, being more suitable to a laboratory environment. It is 
therefore natural that a number of methods have been developed to study β-cell function and 
insulin sensitivity in vivo. 
Some of these tests are easy to perform and can be used as a clinical examination, for example, 
QUICKI and HOMA-IR, which are static tests. These are based on the plasma glucose and 
insulin concentrations at baseline and do not take account of any variation – “the dynamics”. 
These tests were originally designed for population studies in diabetic research (Beard, 
Bergman et al. 1986, Katz, Nambi et al. 2000) but their usefulness in capturing surgery-induced 
changes in insulin resistance is unclear. 
Other tests are more invasive. The intravenous glucose tolerance test (IVGTT) is, together with 
the glucose clamp method, denoted “dynamic tests”. The IVGTT estimates insulin resistance 
from the balance between plasma insulin levels over time (stimulus) and the half-life of glucose 
(effect) throughout the metabolism of an intravenous glucose load. The endogenous insulin 
secretion can also be used as a measure of the β-cell function which of course, can not be used 
during euglycemic glucose clamp (Pacini and Mari 2003). 
The oral glucose tolerance test (OGTT) is considered as a simple test for estimating both 
insulin sensitivity and β-cell function. It is used to diagnose glucose intolerance and diabetes. 
The effects of the oral glucose load are affected by, in addition to insulin secretion and insulin 
sensitivity, other factors such as gastrointestinal glucose absorption. This is probably the reason 
that the method has a relatively poor reproducibility (25% intra-individual variation) (Matsuda 
and DeFronzo 1999, Pacini and Mari 2003). The calculated indices do not bear simple 
relationships with glucose and insulin data, and the insulin sensitivity and β-cell function are 
determined using equations that have an empirical basis. The validity of these indices clearly 
depends on the validity of the assumptions made in determining them; this is the main 
weakness of the OGTT method (Borai, Livingstone et al. 2007). For this reason we refrained 
from using this method. 
The QUICKI and HOMA-IR tests, in contrast, reflect the balance between glucose and 
insulin in the absence of any metabolic challenge, and are believed to reflect hepatic insulin 
resistance (Abdul-Ghani, Jenkinson et al. 2006). The clamp test represents insulin resistance in 
peripheral tissues and in reaction to surgery. 
We wished to develop an IVGTT with a reduced number of data points, without compromising 
measuring accuracy, which would only marginally affect a patient's physiology and plasma 
volume. This improvement would make it possible to use this test in a clinical setting, such as 
surgery, to measure a patient's insulin sensitivity. 
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SURGERY-INDUCED INSULIN RESISTANCE 
Hormones, such as catecholamines, cortisol, glucagon, and growth hormones, cause insulin 
resistance (Thorell, Nygren et al. 1999). Epidural anesthesia blocks catecholamine release 
which reduces the degree of postoperative insulin resistance (Uchida, Asoh et al. 1988). 
Cytokine release may also cause insulin resistance. In addition, the degree of postoperative 
insulin resistance following simple elective procedures is correlated with interleukin-6 (IL-6) 
levels (Thorell, Loftenius et al. 1996). This release of hormones during surgery pushes the body 
into a catabolic state, with increased metabolism and a diversion of nutrients away from their 
previous uses. It also leads to the suppression of immune function through atrophy of lymph 
nodes, decreased lymphocytes and IgA production, and inhibition of cellular immunity 
(Gunerhan, Koksal et al. 2009). The result of this suppression is an increased risk of infection. 
While these mediators may not entirely explain surgery-induced insulin resistance, several 
studies have suggested the involvement of stress hormones and cytokines in the development 
of this condition. 
Insulin resistance develops in both skeletal muscle and adipose tissue in response to surgery 
(Nygren, Thorell et al. 1997). There is also a small but significant increase (10–15%) in glucose 
production after surgery (Nygren, Thorell et al. 1997). 
A recent meta-analysis that included a variety of methods of assessing insulin sensitivity 
suggested that preoperative oral carbohydrates reduce surgery-induced insulin resistance 
(Awad, Varadhan et al. 2013). Some authors have also shown a beneficial effect on surgery-
induced insulin resistance through the use of the same techniques as developed here (Nygren, 
Soop et al. 1998, Soop, Nygren et al. 2001). However, not all studies have demonstrated that 
preoperative oral carbohydrate loading has a beneficial effect on insulin resistance (Vigano, 
Cereda et al. 2012). 
It is still unclear whether the amount of fluid in the carbohydrate drink can, in itself, affect the 
post-surgical reaction. Glucose has the effect of translocating fluid into cells, and this may 
counter the dehydration that occurs during surgery (Stranberg, Hahn 2005, Berndtson, 
Olsson et al. 2008). 
We wanted to study whether the quantity of fluid found in a commonly used carbohydrate 
drink (preOp®) contributes to, or can fully explain, the beneficial effects of the carbohydrate 
drink on surgery-induced insulin resistance. As a further study, we wanted to compare similar 
groups of patients who had received a hip prosthesis to see if a carbohydrate drink affects 
insulin sensitivity and β-cell function, as measured using the glucose clamp technique and 
IVGTT, respectively. 
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3 AIMS OF THE STUDIES 
The overarching goal of this project was to improve the wellbeing of patients undergoing hip 
replacement surgery through modification of fluid and nutritional therapy. 
The first step in this process, and also the general aim of the present Thesis, was to increase the 
opportunities to assess insulin resistance through the use of methods that can be applied in the 
surgical setting. 
The specific individual study aims: 
Study I 
To find a simple intravenous glucose tolerance test (IVGTT) that can be used to 
monitor insulin sensitivity in the surgical setting. 
Study II 
To study whether some of the effects of the carbohydrate drink on insulin resistance 
and wellbeing following elective hip replacement surgery can be attributed to the 
fluid volume component (1.2 L) of the drink. 
Study III 
Due to the results of Study II, this study investigated the effects of 
carbohydrate loading on insulin resistance following elective hip replacement 
surgery using both the IVGTT and the euglycemic hyperinsulinemic clamp methods. 
Study IV 
To compare the effectiveness of commonly used methods (IVGTT, QUICKI and 
HOMA) in assessing surgery-induced development of insulin resistance. 
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Overview 
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4 ETHICS 
All human studies were conducted according to the Helsinki declaration and approved by the 
Ethics Committee of the Karolinska Institutet. The applications have the following 
identification numbers: 
2007/1628-31/4, 
2007/1670-31,  
2011/1141-31/3. 
In all studies (I–IV), each volunteer/patient gave their written consent to participate. 
The studies were also registered at Clinical Trial Gov. 
Study II (NCT 01211184) and  
Study III–IV (NCT 01774084) 
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5 MATERIALS AND METHODS 
Apart from in Study I, all patients were scheduled for elective hip replacement surgery and 
received both oral and written information concerning their participation in the study. 
An overview of study design and methods is presented in Table 1. 
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PARTICIPANTS 
Study I 
Between May 2008 and May 2009, 20 volunteers (8 females and 12 males), aged between18 
and 50 (mean 28) years, were studied. Exclusion criteria were the presence of endocrinological 
disorders. Routine blood chemistry was used to confirm the absence of metabolic disease. 
Study II 
Between May 2008 and September 2009, 60 patients (41 females and 19 males), aged between 
44 and 89 years of age (mean age, 69 years), were studied in an open randomized clinical trial 
(RCT) while undergoing elective total hip replacement under spinal anesthesia. 
Exclusion criteria were the presence of endocrinological disorders, including diabetes, and 
treatment with cortisone. Each patient gave their informed consent to participate. The most 
common diseases affecting the patients included hypertension (n=17), previous thrombosis 
(n=4), chronic obstructive pulmonary disease (n=3), and previous cardiovascular surgery (n=3). 
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Study III 
Between December 2011 and November 2012, 46 individuals were asked to participate in this 
study. Twenty-three subjects (16 females and 7 males), aged between 57 and 76 years (mean: 
68 years), agreed to take part. All patients were scheduled to undergo elective total hip 
replacement surgery at the Orthopedic Departments at Södersjukhuset, Stockholm, Sweden 
and/or Södertälje hospital, Södertälje, Sweden. 
Exclusion criteria were known diabetes, renal impairment (serum creatinine >150 umol/L), 
liver disease, blood hemoglobin (Hb) concentration <110 g/L, severe ongoing infection, 
malignancy and mental illness. After enrolment, one patient in the placebo group decided not to 
participate. 
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Study IV 
This used the same patients as in Study III. Twenty-two non-diabetic patients (15 females and 7 
males), aged between 57 and 76 years (mean 68 years), were studied between December 2011 
and November 2012. Each patient was scheduled to undergo elective total hip replacement 
surgery at the Orthopedic Departments at Södersjukhuset, Stockholm, or Södertälje Hospital, 
Södertälje. Exclusion criteria were known diabetes treated with oral medication or insulin, 
renal impairment (serum creatinine >150 µmol/L), liver disease, severe ongoing infection, 
malignancy, and mental illness. This study was part of a larger project assessing the intake of a 
nutritional drink just prior to surgery (Study III). 
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STUDY DESIGN 
Study I 
This was a methodological study. The volunteers, after 12 h of fasting, reported to the 
metabolic laboratory at Södersjukhuset between 7.30–8.00 AM. Baseline blood samples were 
drawn for measurement of plasma insulin and glucose. A hyperinsulinemic euglycemic clamp 
was then initiated for 120 min. The plasma glucose was measured every 5 min. 
On the second occasion, separated by 1–2 days from the clamp study, and after 12 h of fasting, 
a regular IVGTT was performed. Blood was sampled at 0, 2, 4, 6, 8, 10, 20, 30, 40, 50, 60, and 
75 min. 
Study II 
After all baseline parameters had been measured, each patient was randomly assigned to one of 
three study groups, using the sealed envelope method. This took place in the orthopedics 
department on the day before the surgery. Prior to the start of the study, 60 blank envelopes 
were prepared. The treatment group number was written on a blank piece of paper, in the 
proportion 1:1:1 and one placed in each envelope. The envelopes were mixed together in a 
large bucket and randomly drawn and opened by the research nurse in the presence of the 
patient. 
The groups were: 
• Fasting: no food or water from midnight before the surgery (control).
• Tap water: 800 mL by mouth, 2 h before entering the operating room.
• Nutrition: a carbohydrate drink (50 kcal/100 mL; preOp®, NutriciaNordica AB,
Stockholm, Sweden) 800 mL in the evening before the surgery (Day 0) and 400 mL 2
h before entering the operating room (Day 1).
Cemented total hip replacements were performed under spinal anesthesia (cement was avoided 
in three middle-aged patients). 
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Patient monitoring consisted of pulse oximetry, non-invasive blood pressure and 
electrocardiogram tests. 
At the end of the surgical procedure, patients with anything more than minimal bleeding were 
given 1 g of tranexamic acid intravenously (Cyklokapron, Meda AB, Solna, Sweden). 
Postoperative pain was managed using an epidural catheter with a continuous infusion of 
levobupivacaine and sufentanil (n=22) or a wound catheter with ropivacaine and ketorolac 
(n=25; the hospital practice changed during the study period). All patients were also given oral 
paracetamol. Oral oxycodone served as the rescue pain reliever. 
Measure Day 0 Day 1 Day2 Day 3 Day 14 
Glucose tolerance test  X         X  X 
Surgery X 
Urine collection  
(cortisol, 3-MH) 
  X    X 
Bioimpedance X        X  X 
Complications by protocol X 
Well-being  X X X X X X X X X 
Randomization     X 
A short IVGTT was performed in the fasting state on Day 0, 2 to 3 h after surgery on Day 1, 
and before breakfast on Day 2. Blood samples were taken at baseline and at 10, 20, 30, 45, 60, 
and 75 min. 
Bioelectrical impedance analyses were carried out and the mean of three successive recordings, 
based on the preoperative body weight, was used. 
The serum cortisol concentration was measured 2 to 3 h after the surgery ended. 
Urine samples were collected from the catheter in the urinary bladder, just before the operation 
started and up to the morning of Day 2. A second urinary collection program began on the 
morning of Day 2 and ended on the morning of Day 3. 
The breakdown of muscular protein (3-MH) was quantified in the urine collected on Day 2 and 
Day 3. All patients were served lacto-vegetarian food from the day before surgery (Day 0) and 
throughout their hospital stay to prevent any confounding effects from the ingestion of 
exogenous meat on the excretion of 3-MH. 
29 
The data on complications were collected in three different ways and four scales previously 
used and validated in healthcare assessed life quality. The patient filled in these forms in the 
afternoon on the day before surgery. A research nurse interviewed the patients, and re-
completed the forms, 2 weeks post-surgery. The health index (HI) was also applied on the 
second postoperative day.  
The Swedish text used for these scales is shown in the Appendix. 
Studies III–IV 
The patients reported at the metabolic laboratory at 8 AM on the day before and two days after 
surgery. They underwent an IVGTT (a bolus of glucose of 300 mg/kg in a 30% solution) to test 
β-cell function, followed, approximately 15 min later, by a euglycemic hyperinsulinemic clamp 
to quantify peripheral insulin sensitivity. On both occasions, the patients had fasted since 
midnight 
Upon completion of the first day’s measurements, the patients were randomized using the 
sealed envelope method to receive either tap water (placebo) or the carbohydrate beverage 
(preOp®). The sealed envelope was opened by staff at the laboratory. The research leader and 
the patient were unaware of the randomization result. 
The patients received the fluid in identical containers. They were instructed to ingest one bottle 
containing 800 mL of fluid at bedtime, no later than midnight, and another bottle containing 
400 mL approximately 2 h before surgery. Aside from this fluid, the patients did not receive 
any other beverage or food from midnight until the start of the surgery. 
Ringer’s acetate could be given for volume replacement upon the induction of spinal 
anesthesia. This was administered to all except three patients, who received general anesthesia. 
Infusion fluid during the surgery was provided at the discretion of the anesthetic team. The 
total hip replacement method used was totally cemented, partially cemented or totally cement-
less. 
Postoperative care followed established clinical routines and included free intake of food and 
drink, as well as rehabilitation with a physiotherapist. 
Two days after the surgery, the patients returned to the laboratory for the second insulin 
sensitivity measurement, which was performed using the same procedure as used for the 
preoperative measurement. 
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BIOCHEMICAL ANALYSIS 
Cortisol 
One way of quantifying physical stress is to measure the cortisol formed in the adrenal cortex, 
which is derived from cholesterol. This is the body's main stress hormone. 
The synthesis and secretion of cortisol is stimulated by ACTH (adrenocorticotropic hormone), 
which is formed in the pituitary gland. The concentration of cortisol in plasma follows ACTH's 
diurnal variation, with the highest values in the morning and lowest at midnight. Elevated 
cortisol levels in the blood inhibit the secretion of ACTH and vice versa. 
In the plasma, cortisol is transported primarily bound to transcortin. Approximately 75% of the 
cortisol in circulation is bound to transcortin with the rest bound to serum albumin (Sandberg, 
Woodruff et al. 1964). Only the free fraction (about 10%) is biologically active. Trauma (such 
as surgery), burns, infections, hypoglycemia and other forms of stress will normally greatly 
increase ACTH and cortisol secretion. 
The majority of cortisol is metabolized in the liver and excreted as various inactive derivatives 
in the urine. Normally only small amounts of free cortisol are found in the urine. The binding 
capacity of transcortin will be exceeded if serum cortisol levels are markedly increased, 
resulting in an increase in the excretion of free cortisol in the urine. 
The analysis of serum and/or urinary cortisol levels are essential in investigations of suspected 
adrenal cortex disorders (Turpeinen and Stenman 2003). Elevated values occur in Cushing's 
syndrome, during treatment with ACTH, cortisol and cortisone, as well as during stress. 
Cortisol also affects carbohydrate and fat metabolism. 
Liquid chromatography-tandem mass spectrometry was used for the cortisol analysis (Roche- 
Hitachi Modular E170). (Vogeser 2003, Vogeser and Parhofer 2007). 
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3-metyl-histidine (3-MH) 
3-MH is an amino acid residue of muscle catabolism. It cannot be synthesized or metabolized 
in the body and any 3-MH excreted via the urine must therefore be derived from muscle 
catabolism. 
The concentration of this amino acid was measured in daily urine collections using a Biochrom 
30 amino acid analyzer (Biochrom Ltd., Cambridge, UK) (Bisgaard, Kristiansen et al. 2004, 
Hahn, Ljunggren et al. 2011). The ratio of 3-MH to urinary creatinine was used to compensate 
for incomplete urine samples (Elia, Carter et al. 1981, Sjolin, Hjort et al. 1987). 
The ingestion of meat can cause errors in these measurements and intake of meat was therefore 
prohibited over the first two days for those participating in the study (Elia, Carter et al. 1981, 
Sjolin, Hjort et al. 1987). 
Body fluid volumes (BIA) 
Intracellular volume was measured using multi-frequency bioimpedance (BIA), with a Xitron 
4000B Spectrum Analyzer (Xitron Technologies Inc., San Diego, CA, USA). 
Two stickers were placed on the patient's hands and feet, and a series of approximately 50 
direct currents of various frequencies transmitted through the body. The patient does not feel 
these currents. Electrical current is conducted at different speeds by cells and non-cellular 
items, allowing the calculation of relative volumes (Johnson, Virk et al. 1992, De Lorenzo, 
Andreoli et al. 1997) (Jaffrin and Morel 2008). 
PREOP®
preOp® (NutriciaNordica AB, Stockholm, Sweden), is a clear, non-carbonated, lemon 
flavored, iso-osmolar carbohydrate drink. It contains (per 100 mL); 50 kcal (215kJ) , 0 g fat, 0 
g protein, 12.6 g carbohydrate (100 E%) in the form of maltodextrin and fructose. 
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INSULIN SENSITIVITY AND INSULIN SECRETION 
Clamp techniques 
Insulin affects the circulating plasma glucose by inhibiting glucose release from the liver and 
by stimulation of glucose uptake in the liver and peripheral target organs (skeletal muscle, 
adipose tissue) 
Any quantification of insulin-mediated glucose uptake therefore requires that the glucose 
release from the liver should be negligible, requiring a total inhibition of hepatic glucose 
production. 
Additionally, the circulating insulin level should be entirely determined by the experimental 
conditions. Through the use of various combinations of an insulin–glucose infusion, oral 
glucose levels and/or the circulating insulin levels can be controlled under experimental 
conditions. The clamp technique allows key parameters to be studied, despite the complex 
inter-relationships normally seen between the factors governing glucose turnover. A clamp 
implies that one parameter is deliberately maintained at a controlled level while other 
physiological parameters are changed. The so-called hyperinsulinemic euglycemic clamp 
allows quantitative estimation of insulin-mediated glucose uptake for a given insulin 
concentration. 
Hyperinsulinemic  euglycemic clamp 
The hyperinsulinemic euglycemic clamp is the most accurate method for quantifying insulin-
induced glucose uptake and peripheral insulin sensitivity. 
In our studies, the clamp was initiated approximately 15 min after the IVGTT had ended. 
During the course of the 120 min test, insulin 20 mU BSA.(min.m2)–1 (Human Actrapid, 
NovoNordisk A/S, Bagsverd, Denmark) was infused, along with 20% dextrose (Fresenius 
Kabi, Uppsala, Sweden). A superficial dorsal hand vein was cannulated in the retrograde 
direction with a small three-way needle and kept patent through repeated flushing with a saline 
solution. The hand and lower arm were kept warm with a heating pad (Copeland, Kenney et al. 
1992) during the period of intermittent sampling of arterialized venous blood for glucose 
determination. 
Baseline blood samples were drawn, and the euglycemic hyperinsulinemic clamp was initiated 
through infusion of a bolus dose of insulin for 4 min, followed by a step-wise increase in 
glucose for 10 min. The plasma glucose was measured every 5 min using the glucose oxidase 
method on a YSI 2300 STAT Plus™ (Yellow Springs Instruments, OH, USA). The results 
were used to adjust the insulin rate to keep the subject’s blood glucose levels constant at 5 
mmol/L (DeFronzo, Tobin et al. 1979). 
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Plasma insulin levels and C-peptide concentrations were measured every 15 min. Plasma 
glucose was measured using a Modular P (Roche Diagnostics, Tokyo, Japan), and plasma 
insulin and C-peptide on a Roche-Hitachi Modular E170 (Hitachi, Tokyo, Japan). 
The infusion rate of the glucose during the last 30 min, after correcting for body weight, was 
taken to represent the metabolism of the glucose (Mbw) (DeFronzo, Tobin et al. 1979, 
Ferrannini and Mari 1998, Muniyappa, Lee et al. 2008). 
This method causes a rapid increase in the circulating levels of insulin to a steady state of at 
least 400 pmol/L .
The method ensures that the concentration of glucose is maintained at a normal level through 
an intravenous infusion of glucose which rate is adjusted in is adjusted in response to 
frequent determinations of plasma glucose levels in the arterialized blood. The resultant 
degree of hyperinsulinemia almost completely inhibits hepatic glucose output, and the amount 
of glucose added experimentally is therefore equivalent to the total glucose uptake in 
peripheral tissues. (M value: mg glucose/kg × min), the higher the M-value, the greater insulin 
sensitivity. 
HOMA 
HOMA, which is an abbrevition for HOmeostasis Model Assessment, is mathematical model 
for the assessment of β-cell function and insulin sensitivity, based solely on the determination 
of basal glucose and insulin concentrations in plasma 
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(Wallace, Levy et al. 2004, Muniyappa, Lee et al. 2008, Borai, Livingstone et al. 2011). Using 
a computerized nomogram, the relative degree of β-cell dysfunction, specifically with regard to 
insulin resistance, can be calculated graphically. 
Subject to certain given assumptions regarding the parameters, insulin resistance can be 
calculated as: 
Insulin resistance = P-insulin × P-glucose 
The calculation of β-cell function and insulin sensitivity using to this theoretical model has a 
relatively good correlation with more advanced techniques. However, the reproducibility of the 
method is not said to be particularly impressive, with a variation of over 30% (Matthews, 
Hosker et al. 1985). 
QUICKI 
QUICKI is the inverse of the logarithm of the product of plasma glucose and plasma insulin at 
baseline which is one of the HOMA-equations (Katz, Nambi et al. 2000) (Wallace, Levy et al. 
2004, Muniyappa, Lee et al. 2008). 
MINMOD 
Another less costly method for the determination of insulin sensitivity and insulin secretion in 
vivo is the minimal method (MINMOD) technology (Bergman 1989). 
This method is based on frequent determinations of plasma glucose and insulin levels 
following IVGTT. Mathematical models are used to generate a so-called ‘insulin sensitivity 
index’ from computer processed plasma glucose and insulin kinetics results. This represents 
glucose uptake related to variations in insulin levels (Pacini and Bergman 1986, Nittala, Ghosh 
et al. 2006). 
The method also gives an indication of early and late insulin-secretion patterns. The main 
disadvantage of this method, in addition to the fact that it is based on a series of theoretical 
assumptions, is that it requires a relatively well preserved insulin response. This complicates 
the use of the method in cases of type 2 diabetes. For this reason, a modified version has been 
developed which maximally stimulates the insulin response through the combined 
administration of glucose and sulphonylurea (tolbutamide) (Saad, Steil et al. 1997). 
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IVGTT 
IVGTT is one of the first methods developed for the assessment of peripheral insulin sensitivity 
in vivo. In this method, insulin is injected intravenously, and the rate at which the plasma 
glucose concentration falls is measured. The faster the plasma glucose levels drop the greater 
the insulin sensitivity. 
Two main procedures are used; regular IVGTT (Nadon, Little et al. 1964) and modified FSIGT 
(frequently sampled intravenous glucose tolerance test) (Lin, Chen et al. 2013). In the former, a 
bolus injection of glucose (0.3g/kg) is given intravenously over 30–60 seconds and blood 
samples are collected for 3–4 h. FSIGT is used for subjects with insufficient insulin response. 
In this test an additional insulin injection, or short infusion, (0.03–0.05 U/kg) is administered 
after 20 min. Glucose, insulin and C-peptide concentrations are measured, as they were in our 
study. The advantage of the IVGTT is that it is relatively easy to perform and there good 
correlations are found between estimates of insulin sensitivity using the insulin tolerance test 
and results from the clamp. 
After an intravenous bolus injection of glucose a biphasic insulin response is seen (Fig. 7). 
Initially, there is a rapid and pronounced insulin rise (early phase) which reaches peak levels 1–
3min following administration of glucose (endogenous glucose production continues) and is 
completed after about 10 min (DeFronzo, Tobin et al. 1979).  
After basal sampling, glucose (20% or 30 % glucose solution) is injected over a 1-min period. 
Samples (plasma glucose, insulin, and C-peptide) are collected at frequent intervals over the 
first 10-min period to monitor the early insulin response. Thereafter, samples are taken every 
5–15 min for up to 75 min. 
Fig. 7. 
Insulin- 
response 
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In our study the plasma glucose was measured using the glucose oxidase method on a Modular 
P system (Roche Diagnostics, Tokyo, Japan). The plasma insulin and C-peptide concentrations 
were measured using ELISA kits (Modular E170, Roche Diagnostics). 
The calculation of the early and late insulin response was performed by determining the area 
under the insulin curve (AUCinsulin) over the period of 0–10 min (early response) and 10–75 
min (late response) (Tura, Sbrignadello et al. 2010). In subjects with type 2 diabetes, the early 
response is usually missing, while the late release of insulin is preserved. Normally, the half-
life of glucose is 15–30 min. In type 2 diabetics it is about 40 min. 
COMPLICATIONS 
Complications were dealt with using 3 different approaches. The handwritten medical records 
from the beginning of the intraoperative period up to when the patient left the postoperative 
care unit were used to calculate average systolic blood pressure. The second approach relied on 
a checklist of 18 complications administered by a research nurse. This was based on two 
published schemes (Bennett-Guerrero, Welsby et al. 1999, Brandstrup, Tonnesen et al. 2003) 
and used to register all postoperative adverse events up to Day 3. Finally, an orthopedic 
surgeon, blinded to the randomization process listed the complications seen during the entire 
hospital stay as noted by the hospital staff in the digital medical records. The Swedish text used 
for this checklist is shown in the Appendix. 
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WELL-BEING 
W-BQ12 
The wellbeing questionnaire (W-BQ12) consists of 12 items designed to collect information 
concerning different aspects of psychological wellbeing (Wredling, Stalhammar et al. 1995, 
Pouwer, Snoek et al. 2000). The scale measures ‘energy’ as well as ‘negative’ and ‘positive’ 
wellbeing using four statements to evaluate each factor; the patient can respond using one of 
four levels. Higher values denote a better general wellbeing. 
Health index (HI) 
The HI questionnaire is a Swedish questionnaire used to assess a self-reported health status. 
It is comprised of 10 items, measuring energy, temper, fatigue, loneliness, sleep, vertigo, bowel 
function, pain, mobility and one final item measuring general health status (Nordstrom, Nyman 
et al. 1992). The responses are scored on a 4-grade scale ranging from 10 to 40. A high value 
indicates a high level of self-reported health. 
The HI has been tested for reliability in different patient populations with satisfactory results 
(Cronbach’s alpha 0.77–0.85). When used on the day following surgery, the questions refer to 
the previous 12 h. Answers can be given on one of four levels in which: 1=very poor; 2=rather 
poor; 3=rather good; and 4=very good. The highest possible total HI score is 40 and the lowest 
is 10. This test has been used to study patient’s self-perceived health status after ileal conduit 
urinary diversion surgery (Nordstrom, Nyman et al. 1992) and following laparoscopic 
cholecystectomy (Barthelsson, Anderberg et al. 2008). 
Chalder’s Fatigue Scale (FQ) 
The FQ scale consists of 14 questions covering both the physical and mental aspects of fatigue 
(Chalder, Berelowitz et al. 1993). A ‘yes’ answer to a question about fatigue is graded as 1 and 
a ‘no’ as 2. Uncertain answers are graded as 1.5. The scale has been used to study fatigue in 
cancer (Chalder, Berelowitz et al. 1993) and also in other fields, such as in population surveys 
(Kocalevent, Hinz et al. 2011). 
The translation of the HI from English to Swedish was checked by back-translation. The 
wording was virtually identical except in one question where ‘sleepy or drowsy’ back-
translated to ‘tired or lethargic’. 
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EQ-VAS 
This is a ruler or scale-based method which allows patients to rate their self-perceived health; it 
is the last item of the EQ-5D instrument for the measurement of health outcomes (Group 1990, 
Ostendorf, van Stel et al. 2004).  
(The Swedish text used for these scales are shown in the Appendix.) 
39 
6    CALCULATIONS 
GLUCOSE KINETICS 
The first study (Study I) was designed to develop a simpler method of measuring insulin 
sensitivity compared to the more widespread IVGTT which, using the original method, 
involves measurements made over a 240 min period (Bergman, Ider et al. 1979, Bergman, 
Prager et al. 1987). 
The pharmacokinetics of the glucose load were analyzed using a one-compartment open-model 
(Sjostrand and Hahn 2003). In this model, the plasma concentration (G) at any time (t) resulting 
from infusing glucose at the rate Ro is calculated using the following differential equation: 
where Gb is the baseline glucose, G(t) is the plasma concentration of glucose at any given time 
(t), Vd is the volume of distribution, CL the clearance and CL/Vd the slope of the glucose 
elimination curve. The half-life (T1/2) of the exogenous glucose load was obtained from the 
equation ln 2Vd/CL. Best estimates for the unknown parameters in these models were 
individually calculated for each experiment using non-linear least-squares regression, using the 
mathematical program Matlab (MathWorks, Natick, MA, USA). 
MINMOD 
Glucose and insulin data were also analyzed through the application of the “minimal model” 
(MINMOD) developed by Bergman et al. (Bergman, Ider et al. 1979, Nittala, Ghosh et al. 
2006). This quantifies insulin sensitivity based on the action of insulin in a remote 
physiological compartment, meaning that the insulin exerts its effects following a delay 
following the measurement of the plasma concentration. The MINMOD analysis was applied 
to the data in Study I. This was attempted for Study III but as the estimates necessary for this 
model were not very precise in this study the results are not reported. Our opinion is that 
MINMOD requires more data than those provided by the 7-sample IVGTT in order to be 
reliable. 
))((* )(
dd
o
b
b GtG
V
CL
V
R
dt
GGd
−−=
−
40 
IVGTT 
In order to estimate insulin sensitivity we used glucose kinetic parameters and the AUCinsulin, 
indicating plasma insulin, above baseline during the IVGTT to find equations that best 
described the outcome of the clamp procedure. 
The AUC for plasma insulin was calculated by using the linear trapezoid method; 
Insulin sensitivity  = 10log        
Insulin sensitivity  
HOMA-IR 
The  HOMA-IR (Homeostasis Model of Assessment – Insulin Resistance) model expresses 
insulin sensitivity only as the product of the baseline concentrations of plasma glucose and 
insulin only. 
QUICKI 
Insulin sensitivity was also quantified using the QUICKI method, which is the inverse of the 
logarithm of the product of plasma glucose and plasma insulin at baseline; one of the HOMA-
equations (Katz, Nambi et al. 2000) (Wallace, Levy et al. 2004, Muniyappa, Lee et al. 2008). 
QUICKI = 1 / (log P-glucose + log P-insulin) 
CLAMP 
Insulin-induced glucose uptake during the last 30 min of the test, divided by bodyweight, was 
taken as the insulin sensitivity and is denoted by the symbol Mbw. 
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7    STATISTICS 
The results are presented here as the mean and standard deviation (SD) and, in the case of a 
skewed distribution, as the median (25–75th percentile range). In Study IV the results are given 
only as the median (25–75th percentile range). In all the studies, P<0.05 was considered to be 
statistically significant. The statistical approaches and tests used in each of the four studies are 
specified below. 
STUDY I 
Simple or multiple linear regression analyses, in which r2 is the coefficient of determination, 
were used to express “linearity” when studying the relationship between the Mbw of the glucose 
clamp (control) and various algorithms for insulin sensitivity, derived from data collected 
during the IVGTT. 
The error in the prediction of Mbw associated with each regression analysis was obtained as 
[100% (fitted – measured)/measured]. The change in the prediction error obtained by 
restricting the analysis period from 75 to 40 and 30 min was tested by using Friedman’s test. 
STUDY II 
This study was powered so as to be able to detect a difference in the CL for glucose of 30% 
between any of the study groups and the control group with a certainty of 90%. 
The reference data were obtained from both preoperative and postoperative studies. In non-
diabetic healthy humans, CL has been reported as 0.72 (mean, SD 0.18) (Sjostrand, Edsberg et 
al. 2001) and 0.60 (0.26) (Hahn, Ljunggren et al. 2011). During laparoscopy, CL has been 
measured as 0.21 (0.05) (Sjostrand, Edsberg et al. 2001) and, on the second postoperative day 
in hysterectomy patients, 0.42 (0.08) (Strandberg and Hahn 2005). 
The mean of these values yields a standardized difference of 1.05 which was entered into a 
nomogram. This showed that 18 patients per group were required (Altman 1980) for this study. 
The ability of the study to detect postoperative differences would be greater than that in the 
preoperative situation due to less expected scattering of those data. The means (SD) of 
differences between the groups were evaluated using the variance of analysis (ANOVA). 
Differences were studied with the Kruskal–Wallis test when a skewed distribution was found. 
Changes during the study were evaluated using the Wilcoxon matched-pair test. The incidence 
data were studied with the chi-square test. 
Cronbach´s alpha coefficient was used to test the reliability of the wellbeing tests. 
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Cronbach´s alpha coefficient is the most widely used method for measuring reliability. This 
method uses the degree to which each item in the test is associated with any other item. A good 
degree of reliability can be inferred if similar readings are obtained each time the same thing is 
measured. In practical terms, there should be a correlation dimension of at least 0.7, ideally 
about 0.9, in order for a test to be considered to have good reliability. 
STUDY III 
The size of the study was chosen to detect a difference in the uptake of glucose of 10% at the 
P<0.05 level, with a power of 80%. The calculation was based on a previous study showing an 
intra-individual coefficient of variation for repeated glucose clamps of 5.8% (Soop, Nygren et 
al. 2000). 
The AUCinsulin and the C-peptide concentrations were calculated using the linear trapezoid 
method. 
Comparisons between the paired samples were made with the paired t-test or Wilcoxon’s 
matched-pair test, depending on the distribution. 
Similarly, unpaired data were evaluated by the unpaired t-test or the Mann–Whitney U-test. 
STUDY IV 
Mbw was calculated using the same methods as in Study I. Simple linear regression analysis, 
where r is the correlation coefficient, was used to express linearity for the relationships 
between the insulin resistances derived from the various approaches. 
Differences were studied using the Wilcoxon matched-pair test. 
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8      RESULTS 
STUDY I 
When we performed the glucose clamp we found that Mbw varied 7-fold. Between 2/3 and 4/5 
of this variation could be predicted by linear regression, based on indices of glucose and insulin 
turnover from the data collected during the IVGTT. During the IVGTT, the glucose kinetics in 
three experiments could only be analyzed up to 40 min due to rapid elimination leading to mild 
hypoglycemia. 
IVGTT versus glucose clamp 
We tested different mathematical algorithms when trying to express Mbw using the data 
obtained during the IVGTT. The principle used in this testing was to make a ratio of the 
“pressure” to decrease plasma glucose, which was taken as the AUCinsulin, and the “effect”, 
which was the half-life of the exogenous glucose load. One useful algorithm contained the 
10log of the product of T1/2 for the exogenous glucose load and AUCinsulin. Various 
modifications of the algorithm correlated with Mbw with a linearity of r2=0.63–0.68. Another 
algorithm inserted glucose kinetic parameters and the AUCinsulin in a multiple regression 
equation, which yielded a maximum linearity of r2=0.83 for the relationship between the 
IVGTT and Mbw. This means that up to 83% of the variability in insulin resistance, as obtained 
by the glucose clamp, could be explained by the result of the short IVGTT in these volunteers. 
QUICKI and MINMOD versus the glucose clamp 
We also compared Mbw with QUICKI, HOMA, Bergman's minimal model analysis 
(MINMOD) and an equation recently published by Tura et al (Tura, Sbrignadello et al. 2010). 
This algorithm has the same construction as QUICKI, which uses only the baseline values of 
plasma glucose and insulin. The original QUICKI equation correlated with Mbw with a linearity 
of only r2=0.41, which was still slightly stronger than for other similar expressions, such as 
HOMA-IR (r2=0.35) and the G/I ratio (r2=0.39) (Muniyappa, Lee et al. 2008). 
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STUDY II 
Of the 60 patients initially enrolled, 57 completed the study. Thirty of the 171 AUCinsulin could 
not used due to occasional hemolysis. 
Glucose and insulin 
Baseline values for P-glucose and insulin were quite similar in the different study groups. P-
glucose was 16% higher on Day 1 and another 10% on Day 2. 
Glucose kinetics 
Over the three days, IVGTT showed an increase in P-glucose (8.3, 9.7, and 9.9) and a decrease 
in CL, with no difference between the groups. T1/2 increased on both days but mostly on Day 1. 
Insulin 
The mean plasma insulin response to the IVGTT decreased on Day 1, but showed an increase 
of 18% on Day 2. AUC changed from –36% to +51% between Day 1 and Day 2. The same 
pattern was found in all three groups. 
Mbw fell on Day 2 but was essentially unchanged on Day 1. When we compared the two 
methods of calculation, i.e., IVGTT against QUICKI, the decline was significantly greater with 
the IVGTT, –48% vs. –8% (Fig. 8). 
Fig. 8. 
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Physical stress, catabolism and body fluid volumes 
There were no statistical differences between the groups with regard to plasma-cortisol 
postoperatively. U-cortisol decreased by 26% between Day 1 and Day 2. There were no 
differences in muscle breakdown (U-3MH/creatinine ratio) between the groups, although the 
excretion rate generally decreased between Day 2 and Day 3. 
ECF was unchanged by the surgery but ICF tended to increase slightly. 
Complications 
Pain, nausea and hypotension were the most common complications. The nurse follow-up 
showed that a mean of 1.5 complications had occurred per patient by Day 3. A mean of only 
0.3 complications per patient was recorded in the digital journal. There was no 
hemodynamic difference between the groups before or after the operation. There was no 
statistical difference in the length of hospital between groups. 
Wellbeing 
No statistically significant difference was seen in general well-being, which improved slightly 
after surgery.  Cronbach´s alpha coefficients for the responses to the W-BQ12, HI, and FQ tests 
before surgery were 0.80 (mean of the three parts), 0.85, and 0.87, respectively. Two weeks 
after surgery, the corresponding values were lower: 0.72, 0.71, and 0.71. 
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STUDY III 
Of the 23 patients enrolled in the study, one patient dropped out due to personal reasons. 
Hemolysis was detected in the insulin samples from two patients, meaning that their AUCinsulin 
could not be calculated. Their results are, however, reported with respect to other parameters, 
including the glucose clamp measurements.There were no statistically significant differences 
with respect to demography, preoperative morbidity and operation details. 
Glucose and insulin at baseline 
The baseline values for plasma glucose concentration were higher after, compared with before, 
surgery (+9%, P<0.01). The baseline values for plasma insulin concentration were only higher 
in the nutrition group (31%, P<0.01). The baseline C-peptide concentrations tended to be 
higher after surgery in the nutrition group (+28%), but the difference from the preoperative 
value did not reach statistical significance (P= 0.11). 
IVGTT 
The half-life of exogenous glucose injected during IVGTT was longer after surgery (mean 29 
vs. 37 min, P<0.02), and the total AUC of plasma insulin and C-peptide larger (P<0.01). The 
early phase (0–10 min) of the AUC for plasma C-peptide was larger after the operation 
(P<0.05), but not for plasma insulin. 
Compared with the preoperative measurement, the second IVGTT in the nutrition group was 
followed by significantly higher plasma insulin concentrations compared with the 
corresponding changes in the control group. This was the case for both the first and second 
phases of insulin secretion, as well as for the total AUC (P<0.05). There was a similar trend 
with respect to the AUC for the plasma C-peptide, but the differences between the groups were 
not statistically significant. However, the differences between these groups were significant 
when the C-peptide concentrations were corrected for plasma glucose. Hence, the ratio of AUC 
for C-peptide and plasma glucose concentrations changed by +46% (2–70) in response to the 
surgery in the nutrition group, whereas there was no such change after the surgery in the 
control group where the difference was –5% (–13 to +16, P<0.03). 
Glucose clamp 
The glucose clamp showed that insulin sensitivity had decreased after surgery (P<0.01). The 
median decrease was 45%. There was no statistically significant difference between the groups 
with regard to the degree of insulin resistance that developed in response to the surgery. 
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STUDY IV 
Missing data reduced the number of evaluable patients to 20. The plasma insulin concentrations 
after 90, 105 and 120 min (when the insulin sensitivity was measured) were 555 pmol/L (483–
651) before surgery and 455 pmol/L (390–531; n=63) afterwards, which confirms that 
maximum insulin stimulation was achieved. The baseline concentration was 60 (42–93) 
pmol/L. 
The glucose clamp showed a 10-fold spontaneous variation in Mbw. A highly statistically 
significant linear relationship was observed between the insulin sensitivity measured by the 
IVGTT and by the glucose clamp before and after surgery. The pre- and postoperative 
measurements were also pooled to obtain the correlation regardless of point in time (Fig.9). 
. 
Similarly, statistically significant correlations were found between the QUICKI and HOMA 
methods and the glucose clamp. 
The precision with which the three algorithms could predict the Mbw obtained by the clamp 
before and after surgery was better for the IVGTT (median absolute prediction error 18%) 
compared to QUICKI (29%; P< 0.03) and HOMA (31%, P< 0.001). Surgery-induced insulin 
resistance amounted to 45% (glucose clamp), 26% (IVGTT), 4% (QUICKI), and 3% 
(HOMA). Despite reasonably good linear correlations, the static tests grossly underestimated 
the degree of insulin resistance that developed in response to surgery.
Fig. 9. 
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9       GENERAL DISCUSSION 
INSULIN RESISTANCE 
All forms of physical trauma induce a variety of complex mechanisms designed to cope with 
the strain it places on the body. Surgery creates physical stress, triggers a cascade of reactions, 
including a transient reduced insulin sensitivity (Ljungqvist, Nygren et al. 2000), increases 
stress hormone secretion, and increases muscle breakdown (Hedstrom, Ljungqvist et al. 2006, 
Ljungqvist, Soop et al. 2007). These reactions may induce nausea and fatigue, and additionally 
affect convalescence for several weeks after surgery (Hausel, Nygren et al. 2005) (Ashby, 
Grocott et al. 2008, Lauwick, Kaba et al. 2009). 
Several studies have shown that the transiently reduced insulin sensitivity, which is similar to 
type 2 diabetes, might be limited or prevented by providing exogenous insulin (Brandi, 
Frediani et al. 1990), a preoperative infusion (Ljungqvist, Thorell et al. 1994, Nygren, Thorell 
et al. 1998) or oral administration of glucose (Nygren, Soop et al. 1999). The studies 
demonstrating a reduction in surgery-induced insulin resistance have encouraged many surgical 
units around the world to implement a carbohydrate drink in their daily patient care. 
A prerequisite for Study II was the idea that ingestion of a carbohydrate-rich drink before 
surgery would alleviate the subsequent development of insulin resistance. We questioned 
whether this effect could be attributed only to the carbohydrates and hypothesized that the 
effect could, alone or in part, be due to the fairly large volume of water in the drink (1.2 L).  
The reason to why water could work is that glucose translocates fluid into the cells. This fluid 
shift might counteract the dehydration that seems to initiate surgery-induced catabolism 
(Häussinger 1995, Strandberg and Hahn 2005). Providing tap water also prevents dehydration 
of the cells, which is an effect that can not be achieved by the electrolyte solutions (such as 
Ringer´s acetate) routinely given for intravenous hydration in the perioperative period.  
Our results show that preoperative fasting and ingestion of the nutritional drink were followed 
by the same degree of urinary cortisol excretion, muscle catabolism, and length of hospital stay. 
Neither the preoperative intake of tap water nor of a nutritional drink alleviated the reduction of 
glucose clearance that occurs after elective hip replacement surgery. Moreover, there was no 
evidence that these treatments affected insulin sensitivity, hemodynamics, the incidence of 
postoperative complications, or patient wellbeing. 
Previous researchers have claimed that carbohydrate drinks improve wellbeing as well as 
reducing nausea and vomiting (Ljungqvist, Thorell et al. 1994, Nygren, Thorell et al. 1998, 
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Wang, Wang et al. 2010). These results have not been consistent (Henriksen, Hessov et al. 
2003, Bisgaard, Kristiansen et al. 2004), and our Study II could not confirm this claim. 
This result was a little bit surprising, considering what other studies had shown. Some authors 
had even shown a beneficial effect on surgery-induced insulin resistance by using the same 
techniques that we have (Nygren, Soop et al. 1998, Soop, Nygren et al. 2001). However, not all 
studies have demonstrated a beneficial action on insulin sensitivity following preoperative oral 
carbohydrate loading (Vigano, Cereda et al. 2012). A meta-analysis by Awad et al(Awad, 
Varadhan et al. 2013)., including 21 RCTs, examines the effects of preoperative carbohydrate 
treatment on clinical outcomes in patients undergoing elective surgery. The only group that 
showed a clear result, when it came to the reduction of length of hospital stay, was patients 
undergoing major abdominal surgery. Furthermore no differences were found with regard to 
the occurrence of postoperative complications following preoperative carbohydrate treatment, 
despite the reduction in postoperative insulin resistance (Awad, Varadhan et al. 2013). 
As the 7-sample IVGTT that we used in Study II had not been compared with the gold 
standard (the hyperinsulinemic glucose clamp) in the age group undergoing hip 
replacement surgery we could not be certain that our measurements accurately showed the 
effect of the carbohydrate drink on insulin sensitivity. To further investigate the 
surprising lack of a difference in insulin sensitivity between the fasting and carbohydrate-
loaded patients in Study II, we did compare insulin sensitivities as measured by both the 
glucose clamp and the IVGTT in Study III. 
Study III had basically the same structure as Study II, i.e. we performed an IVGTT the day 
before surgery but added a clamp test shortly afterwards (Tripathy, Wessman et al. 2003, 
Laakso, Zilinskaite et al. 2008). The patients were randomized to receive either flavored water 
(control) or carbohydrate-rich beverage (preOp®). Two days after surgery, the subjects 
underwent the same tests again. The results confirmed the anticipated decline in insulin 
sensitivity after hip replacement surgery, but there was no statistically significant 
difference in the surgery-induced change in insulin sensitivity between the groups 
regardless of whether the preoperative drink consisted of carbohydrates and water or only 
water. This finding supported the result of Study II. 
The relative reduction in insulin sensitivity in this study is in line with other recent studies 
(Nygren, Soop et al. 1998, Soop, Nygren et al. 2001). There was a trend for less of a reduction 
in insulin sensitivity in the control group (39%) compared to the nutrition group (51%). The 
reason for this is not clear; however we cannot entirely rule out that some of the beneficial 
effects seen in the carbohydrate oral fluid treatment studies(Nygren, Soop et al. 1998, Nygren, 
Thorell et al. 2001) could be attributed to the volumetric component of the drink rather than the 
nutrients (Nygren, Thorell et al. 1998). We earlier found (Study II) no difference in 
intracellular volume expansion between groups receiving carbohydrate loading or water 
ingestion prior to elective hip replacement surgery. A slightly increased intracellular volume 
expansion was demonstrated, in both groups, compared the patients being in the fasting 
state.
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We also demonstrated in Study III, by performing the IVGTT, that endogenous insulin 
production increased in conjunction with preoperative administration of carbohydrate-rich 
beverage. The assessment of pancreatic β-cell function in humans is challenging because of the 
complex interplay between insulin secretion, insulin sensitivity and hepatic insulin extraction; 
comprising the disposition index (Kahn 2003). Thus, in individuals without diabetes, the 
insulin response to an IVGTT is greater than that seen in an insulin-resistant subject, whereas 
the insulin response is less in insulin-sensitive subjects, according to the disposition index 
(Kahn 2003). 
In view of this, the insulin response was measured in our study, using IVGTT, and compared to 
changes in insulin sensitivity (M-value). The first fast-phase of insulin secretion (over the 
initial 0–10 min) is particularly important in terms of β-cell function. As the glucose kinetics 
were similar between the groups, the increased insulin response to preOp®, compared to the 
control group, seems to be driven by the reduction in the induced insulin resistance evoked by 
surgery. This might be explained by over-compensation in insulin secretion, something 
observed in the early stages of insulin resistance. 
Earlier studies also demonstrated that a preoperative carbohydrate drink reduces complications 
(Nygren, Soop et al. 1999, Svanfeldt, Thorell et al. 2005, Ljungqvist, Soop et al. 2007, Li, 
Wang et al. 2012). We did not find any such reduction in complications in Study II, but 
previous studies have based their conclusions on larger groups of patients (Sato, Carvalho   
2010 et al.). 
METHODS 
One problem when assessing glucose metabolism and insulin resistance is that the 
measurements are demanding and complex. The principle tests used are the hyperinsulinemic 
euglycemic clamp (DeFronzo, Tobin et al. 1979), the gold standard in measuring insulin 
sensitivity, and the IVGTT (Borai, Livingstone et al. 2007, Muniyappa, Lee et al. 2008) which 
measures β-cell activity, i.e., insulin secretion, but can also be used to calculate insulin 
sensitivity (Pacini and Mari 2003). The clamp procedure has such a large effect on the body's 
metabolism that this test cannot be repeated in a surgical setting without altering the physiology 
it aims to study. From this point of view, the IVGTT is less problematic. However, the 
traditional IVGTT is still labor-intensive as it requires the analysis of a very large number of 
blood samples. 
For these reasons we wished to develop an IVGTT based on a reduced number of data points, 
without compromising measuring accuracy, and only marginally affecting patient physiology 
and plasma volume (Study I). This improvement would make it possible to use the IVGTT 
during clinical work, such as surgery, to assess the patient's insulin sensitivity. 
When comparing a short IVGTT with the hyperglycemic glucose clamp in 20 volunteers, we 
found that reducing the sampling time from 75 min to 40 min, or even 30 min, had only 
minimal effects on our quality measures, i.e., linearity and prediction errors. Our short IVGTT 
was also more reliable than QUICKI and HOMA-IR methods. These tests are based on plasma 
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glucose and insulin concentrations at baseline and do not take the dynamics of a process into 
account. These two tests were originally designed for population studies in diabetic research 
(Beard, Bergman et al. 1986, Katz, Nambi et al. 2000) but their usefulness for capturing 
surgery-induced changes in insulin resistance has long been unclear. 
Analysis of the 7-sample IVGTT used endogenous insulin secretion in response to an 
exogenous glucose bolus to quantify the balance between plasma insulin over time (stimulus) 
and the half-life of glucose (effect) throughout the disposition of an intravenous glucose load. 
The QUICKI and HOMA methods, in contrast, reflect the balance between glucose and insulin 
in the absence of any metabolic challenge and are believed to reflect hepatic insulin resistance 
(Abdul-Ghani, Jenkinson et al. 2006). The benefits are that they can be used in clinical 
medicine and can be repeated, however, they do not perfectly correlate with the glucose clamp 
(Study I and IV).   
In Study IV we investigated the accuracy of the QUICKI and HOMA algorithms and the 
simplified IVGTT in quantifying insulin resistance, as determined by the glucose clamp, when 
applied to the clinical situation. We used the data from Study III, from the baseline samples and 
the IVGTT at 0, 10, 20, 30, 40, 50, 60, and 75 min for the measurement of the plasma glucose 
(P-glucose) and insulin (P-insulin) concentrations and compared them with the glucose clamp. 
We used the calculations that I described in the Calculations section above, and found that our 
7-sample IVGTT, QUICKI and HOMA all correlate reasonably well with the result of the 
glucose clamp for single points in time, although the linearity and precision were slightly 
poorer for the QUICKI and HOMA than for the 7-sample IVGTT. However, the QUICKI and 
HOMA did not capture the severity of the insulin resistance that developed in response to 
surgery. These algorithms indicated a change of only 3–4% while the glucose clamp showed an 
increase in insulin resistance of 45%. Consequently, these algorithms cannot be used to assess 
changes in insulin resistance that occurs during surgery. The IVGTT reflected the surgery-
induced changes more accurately, but it still did not completely correlate with the clamp. 
We concluded that if we sampled data more frequently, so as to capture the early insulin 
response seen during the first 10-min after injection of the exogenous glucose, we would yield 
a 6% larger AUCinsulin and that the IVGTT would agree more closely with results obtained by 
the glucose clamp. The reader may note that the first 10-min was included in Study I. However, 
this improvement of the IVGTT suffers from the practical problems involved in taking blood 
samples every 2 min between 2 and 8 min. The 7-sample IVGTT that we suggest uses samples 
taken from 10 min onward. 
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LIMITATIONS 
Study II, compared to Study III, was non-blinded as blinding was considered difficult to carry 
out for the fasting group. The study protocol was also based on the assumption that the 
nutritional drink would preserve insulin sensitivity and reduce the incidence of complications, 
so that the focus was on postoperative comparisons between the groups. This fact explains 
why cortisol and 3-MH were not measured preoperatively. As the study was powered 
to discover differences in glucose clearance, conclusions with regard to insulin sensitivity, 
postoperative complications and wellbeing would probably require larger study groups for 
firm conclusions to be safely drawn. However, the lack of even a trend towards benefits 
as a result of the intervention is striking. 
The clamp technique, regarded as the gold standard, was not used to measure insulin sensitivity 
in Study II, although intravenous glucose tolerance is a widely accepted alternative. 
The relatively sparse sampling scheme in Study II, which was motivated by ethical 
considerations regarding maximum blood sampling volume, has been validated against the 
hyperglycemic glucose clamp used in Study I. The sparse sampling scheme used for the 
IVGTT in all studies also made it difficult to apply Bergman´s MINMOD kinetics method with 
confidence. The MINMOD set of equations were programmed in the Matlab environment but 
yielded parameter estimates with confidence intervals too wide to be useful. 
Hemolysis in some insulin samples made the reported values too uncertain to be included in 
calculations of the AUC. As a result, 18% of the AUC´s for insulin had to be deleted, which 
resulted in insulin sensitivity being based on less data than originally intended. 
One should note that we did not use a tracer technique (Dalla Man, Piccinini et al. 2013) with 
the clamp to quantify the endogenous glucose production. However, the endogenous glucose 
production is strongly inhibited by high insulin concentrations, and should be very small when 
the insulin sensitivity is assessed at the end of the glucose clamp procedure. Moreover, the 
glucose uptake elicited by maximal insulin stimulation was measured with an insulin dose 
lower than that originally suggested by DeFronzo (DeFronzo, Tobin et al. 1979). The lower 
dose is routinely used in our metabolic laboratory since it is safer and the plasma insulin 
concentrations hardly differ between the two (400-500 pmol / l for the higher one) (Nystrom, 
Gutniak et al. 2004)). Accordingly we used different doses of glucose in the Study II (0.2 g/kg) 
compared with Study III-IV (0.3 g/kg).   
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   Fig. 10          Fig. 11 
A theoretical problem when using the IVGTT is that the peak plasma glucose 
concentration will exceed the renal limit for glucose conservation (Fig. 10 A), and some of the 
injected glucose will therefore appear in the urine. Moreover, the hypertonic nature of the 
injected glucose will translocated fluid from the cells to the plasma, causing plasma volume 
expansion that is far greater than the volume of the injected glucose solution (9%, see Fig. 10 
B). These problems are of little consequence in young volunteers as shown in the Fig. 10 which 
is derived from data in Study I. However, in the elderly subjected to surgery, the 
hyperglycemia and might be more pronounced and the plasma volume expansion 
have hemodynamic consequences.  
Before Study II was initiated, we performed computer simulations based on glucose and 
volume kinetic data from Study I to find out whether a smaller dose of glucose injected over a 
longer period of time than 1 minute could minimize these problems. The results are not 
included in the present Thesis but published elsewhere (Hahn & Nyström 2011). It was found 
that the extending the injection time from 1 to 4 minutes and reducing the glucose dose from 
0.3 to 0.2 g/kg could markedly alleviate the both the hyperglycemia (Fig. 11 A) and the sudden 
plasma volume expansion hyperglycemia (Fig. 11 B) resulting from the IVGTT.    
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FUTURE PERSPECTIVES 
Our 7-sample IVGTT is fairly simple to implement and might have a place in clinical 
medicine. Currently, relatively little is known about insulin resistance and its relation to 
surgery. Using our method it might, for example, be possible to follow what happens with 
insulin resistance during and after gastric bypass surgery for obesity, which is of great interest 
to many people nowadays. Furthermore, it may be useful in cases of severe illness, patients 
with ASA grade ≥III, diabetes or in those undergoing emergency surgery. Furthermore, it 
would be interesting to compare the different measurement methods in patients who also have 
diabetes or other metabolic diseases. 
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10     CONCLUSIONS 
• It is possible to shorten the IVGTT to enable measurement of insulin resistance under
clinical conditions (Study I).
• We could not demonstrate any differences between preoperative fasting, water
ingestion or a carbohydrate-rich drink with respect to hemodynamics, postoperative
complications or wellbeing after elective hip replacement surgery (Study II).
• There were no statistically significant differences between water and a carbohydrate-
rich drink with regard to the reduction of glucose clearance. These treatments were 
followed by the same decrease in insulin sensitivity after the surgery (Study II and Study 
III).
• Our short seven-sample IVGTT shows better correlation with the gold standard, the 
euglycemic hyperinsulinemic clamp, than QUICKI and HOMA-IR (Study IV).
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11      SAMMANFATTNING (SUMMARY IN SWEDISH) 
Det är välkänt att kirurgiskt trauma startar en rad olika fysiologiska reaktioner i kroppen, bl.a. 
en övergående insulin resistens liknande typ 2 diabetes, stress hormon sekretion (cortisol) och 
sannolikt en obalans i kroppsvätskefördelningen. Det katabola tillstånd som triggas igång 
medför också en nedbrytning av muskulatur. Den påverkan på allmäntillståndet som uppträder 
efter kirurgi har kopplats till en övergående insulinresistens. Man har tidigare visat i studier att 
man kan förebygga detta genom att ge patienten kolhydratrik vätska innan kirurgi. 
Vi funderade på om man det var den tillförda vätskemängden i sig som påverkar 
insulinresistensen än kolhydrattillförseln. För att kunna mäta detta i kliniskt bruk så var vi 
tvungna att ta fram ett mer förenklat test att mäta insulinresistensen än vad de tester som fanns 
att tillgå, som var mer för mätning i laboratoriemiljö än för kliniskt bruk. 
Studie I; en metodstudie, med 20 friska frivilliga försökspersoner, där vi önskade att förenkla 
ett 120 minuters intravenöst glukostolerans test (IVGTT). Vi gjorde jämförelser mellan 
olika kinetiska parametrar med insulinkänsligheten (Mbw) mätt med ”gold 
standard”- hyperinsulinemisk euglykemisk clamp. Plasma glukosvärdet användes för att 
beräkna distributionsvolymen(Vd) och clearance (CL) för den tillförda intravenösa 
bolusdosen av glukos.  Plasma insulin svaret kvantifierades genom att mäta arean under 
kurvan för insulin ( AUCins ) , vilket återspeglar ”styrkan” av svaret. Vi prövade olika 
algoritmer baserade på glukoselimineringskurvans lutning i kombination på AUCins. 
Vi fann att vi kunde reducera mätpunktsintervallet från 180 minuter till 30-40 minuter med vårt 
förenklade IVGTT, till 7 mätpunkter, med kvarstående stark korrelation, mellan 2/3 och 4/5, 
mot clampen. 
Studie II; en randomiserad kontrollerad studie (RCT) med 60 patienter, utan diabetes, som var 
planerade för höftprotesoperation. De randomiserades till att fasta (kontroll), dricka smaksatt 
vatten (placebo) eller kolhydratrik vätska (preOp®) före operation. Vi utförde ett IVGTT dagen 
innan operation, direkt efter operationen på den postoperativa avdelningen, samt dagen efter 
operationen. 
Vi beräknade glukos-clearance och insulinresponsen (β-cellsfunktionen), mätte urin- och 
plasmacortisol samt muskelnedbrytning (urin-3-methylhistidin). Vi registrerade eventuella 
komplikationer samt patienterna fick fylla i olika välbefinnandeformulär vid olika tidpunkter. 
Vi fann ingen statistisk skillnad beträffande glukosclearance, insulinsensitiviteten, 
postoperativa komplikationer eller välbefinnande mellan vatten och den kolhydratrika vätskan. 
Studie III; en dubbelblind RCT med 23 patienter utan diabetes som var planerade för en 
höftprotesoperation. De randomiserades till antingen smaksatt vatten (placebo) eller kolhydrat 
rik vätska (preOp®) före operation. Vi beräknade insulinrespons (IVGTT) och 
insulinsensitivitet (Mbw) dagen före samt två dagar efter operation. 
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Vi fann en signifikant men liknande minskning av insulinsensitiviteten mellan grupperna, men 
kolhydratgruppen visade en ökad β-cellsaktivitet vilket kan bero på en möjlig 
överkompensation i insulinsekretionen. Detta har man tidigare kunnat se tidigt i förloppet vid 
insulinresistens. 
Studie IV; en observationsstudie med 22 patienter från studie III där vi jämförde två 
dynamiska test(vårt korta 7-provs IVGTT och euglykemisk hyperinsulinemisk clamp) med två 
statiska test (”QUICKI” och HOMA-IR). De senare testerna  baseras endast på utgångsvärdena 
av plasma-glukos och -insulin. Clampen fungera som kontroll-metod (=rätt svar). 
Vi fann att det förelåg en svagare linjäritet och ett större residualfel vid användning av QUICKI 
och HOMA-IR än vid IVGTT när vi uppskattade insulinresistensen före och efter operation. 
Dessa två underskattade också grovt graden av insulinresistensen vilket för tanken till att 
kirurgiinducerad insulinresistens kan bero på förändringar hos de perifera vävnaderna, såsom 
muskel och fettvävnad, men inte på leverns. 
Slutsats 
Vi kan med vårt förenklade 7-provs IVGTT mäta den insulinresistens som uppkommer i 
samband med kirurgi med kvarstående stark korrelation till ursprungsmetoden (clamp) vilket 
gör det möjligt att använda metoden i klinisk miljö. Vi har även funnit att det inte föreligger 
någon statistisk skillnad mellan intag av vatten eller kolhydratrik dryck innan operation 
beträffande minskningen av insulinsensitiviteten. Vi fann heller ingen uppenbar skillnad mellan 
grupperna när det gäller välbefinnande, och komplikationer efter höftprotesoperation.  
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13      APPENDIX 
KOMPLIKATIONER 
Gradera som 0-1-2-3 (svårighetsgrad) och beskriv kortfattat! 
1. Ventilationshjälp (syrgas, ventilator m.m.) ___________________________________
2. Feber och antibiotika utan känt fokus _______________________________________
3. Smärta (opioider behövs) _________________________________________________
4. Illamående och kräkningar  _______________________________________________
5. Högt/lågt blodtryck   ____________________________________________________
6. Hjärtarrytmier _________________________________________________________
7. Tolererar inte fast föda __________________________________________________
8. Neurologiska probloem (förvirring etc.)   ____________________________________
9. Sårkomplikation   ______________________________________________________
10. Hemtologisk komplikation (blodtransfusion etc.)  ____________________________
11. Njurproblem   _________________________________________________________
12. Postspinal huvudvärk   __________________________________________________
13. Blodförgiftning (sepsis)   ________________________________________________
14. Lunginflammation   ____________________________________________________
15. Lungödem   __________________________________________________________
16. Hjärtinfarkt  __________________________________________________________
17. Stroke   ______________________________________________________________
18. Inflammation i urinblåsan   _______________________________________________
Annat (beskriv)____________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
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W-BQ12 
Hela tiden Inte alls 
1. Jag gråter ibland eller känner mig gråtfärdig.      3    2     1      0 
2. Jag känner mig nedstämd och tungsint.
3. Jag känner rädsla utan någon som helst orsak.
4. Jag blir lätt upprörd eller skärrad.
5. Jag känner mig energisk, aktiv och pigg.
6. Jag känner mig slö och trög.
7. Jag känner mig trött, utsliten eller slutkörd.
8. Jag känner mig fräsch och utvilad när jag
vaknar.
9. Jag har varit lycklig, nöjd och tillfreds med
mitt  personliga liv.
10. Jag har levt det liv som jag har önskat.
11. Jag har känt mig ivrig att ta itu med dagliga
göromål eller att fatta nya beslut.
12. Jag har känt att jag lätt kunnat handskas med
eller klara av allvarliga problem eller större
förändringar i mitt liv.
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HÄLSOINDEX 
1. Hur är det med Din ork?
Orkar ingenting orkar ganska lite orkar ganska mycket orkar nästan hur mycket som helst 
□ □ □ □
------------------------------------------------------------------------------------------------ 
Hur är det med Ditt humör? 
Är så ledsen är ganska ledsen är ganska glad är så glad man kan bli 
□ □ □ □
------------------------------------------------------------------- 
2. Hur trött känner Du dig?
Mycket trött ganska trött inte särskilt trött inte alls trött 
□ □ □ □
----------------------------------------------------------------------------------------------------------------- 
3. Känner Du Dig ensam och isolerad?
Mycket ensam   ganska ensam   inte särskilt ensam              inte alls ensam 
□                  □                   □                           □ 
------------------------------------------------------------------- 
5. Hur är din sömn?
Sover mycket dåligt    sover ganska dåligt     sover ganska bra   sover mycket bra 
□                  □                   □                           □ 
------------------------------------------------------------------- 
6. Har du yrsel?
Har ständig yrsel har ofta yrsel har sällan yrsel har aldrig yrsel 
□ □ □ □
-------------------------------------------------------------------
- 
7. Hur tycker Du att Din mage fungerar?
   □                  □                   □                           □ 
-------------------------------------------------------------------- 
Har mycket besvär har ganska mycket har lite besvär med har inget besvär 
med magen besvär med magen magen alls med magen 
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8. Besväras Du av värk eller smärta?
 Har ständig värk har ofta värk har sällan värk har aldrig värk 
□ □ □ □
----------------------------------------------------------------- 
9. Har Du svårt att röra dig?
   Har mycket svårt har ganska svårt har lite svårt att är inte alls 
  att röra mig 
□ 
att röra mig 
□ 
röra mig 
□ 
hindrad 
□
------------------------------------------------------------------ 
10. Hur har Din hälsa varit i stort den senaste veckan?
 Mycket dåligt ganska dåligt ganska bra mycket bra 
□ □ □ □
------------------------------------------------------------------ 
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FQ 
Fysiska symtom 
1. Har du problem med trötthet?
2. Skulle du vilja vila med (oftare)?
3. Känner du dig trött eller slö?
4. Har du problem med att komma igång med saker?
5. Kommer du igång med saker utan svårighet men blir svagare med tiden?
6. Känner du brist på energi?
7. Har du för lite styrka i dina muskler?
8. Känner du dig svag?
Mentala symtom 
1. Har du svårt att koncentrera dig?
2. Har du svårt att tänka klart?
3. Har tungan svårt att formulera orden när du talar?
4. Finner du ibland svårt att hitta rätt ord?
5. Hur är ditt minne
6. Har du förlorat intresse för saker som brukade roa dig förr?
64 
EQ- VAS 
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